1-9 of 9
Hidetoshi Hayashi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)

Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3207–3213.
https://doi.org/10.1158/1078-0432.CCR-22-0602
Published: 02 August 2022
View article titled, Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
Open the PDF for Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 893–902.
https://doi.org/10.1158/1078-0432.CCR-21-3194
Published: 01 March 2022
View article titled, A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <em>EGFR</em>-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Open the PDF for A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <em>EGFR</em>-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) in another window
Includes: Supplementary data
Journal Articles

Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 428.
https://doi.org/10.1158/1078-0432.CCR-21-4240
Published: 19 January 2022
View article titled, Correction: KRAS Inhibitor Resistance in <em>MET</em>-Amplified <em>KRAS</em><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Open the PDF for Correction: KRAS Inhibitor Resistance in <em>MET</em>-Amplified <em>KRAS</em><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms in another window
Journal Articles

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 390–403.
https://doi.org/10.1158/1078-0432.CCR-21-3359
Published: 15 January 2022
View article titled, HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Open the PDF for HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5697–5707.
https://doi.org/10.1158/1078-0432.CCR-21-0856
Published: 01 October 2021
View article titled, KRAS Inhibitor Resistance in <em>MET</em>-Amplified <em>KRAS</em><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Open the PDF for KRAS Inhibitor Resistance in <em>MET</em>-Amplified <em>KRAS</em><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms in another window
Includes: Supplementary data
Journal Articles

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Takashi Ogura, Tadashi Ishida, Akihiko Ito, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 2037–2046.
https://doi.org/10.1158/1078-0432.CCR-19-2027
Published: 15 April 2020
View article titled, Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <em>EGFR</em> Mutation–Positive Non–Small Cell Lung Cancer
Open the PDF for Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <em>EGFR</em> Mutation–Positive Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Sigeki Kato, Osamu Maenishi, Kazuko Sakai, Yasutaka Chiba, Takafumi Okabe, Keita Kudo, Yoshikazu Hasegawa, Hiroyasu Kaneda, Michiko Yamato, Kenji Hirotani, Masaaki Miyazawa, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2653–2664.
https://doi.org/10.1158/1078-0432.CCR-17-2852
Published: 31 May 2018
View article titled, B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Open the PDF for B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity in another window
Includes: Supplementary data
Journal Articles

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

Masato Terashima, Yosuke Togashi, Katsuaki Sato, Hiroshi Mizuuchi, Kazuko Sakai, Kenichi Suda, Yu Nakamura, Eri Banno, Hidetoshi Hayashi, Marco A. De Velasco, Yoshihiko Fujita, Shuta Tomida, Tetsuya Mitsudomi, Kazuto Nishio
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (14): 3663–3671.
https://doi.org/10.1158/1078-0432.CCR-15-2093
Published: 14 July 2016
View article titled, Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of <em>DDR2</em>
Open the PDF for Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of <em>DDR2</em> in another window
Includes: Supplementary data
Journal Articles

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, Kazuko Sakai, Kaoru Tanaka, Hidetoshi Hayashi, Hiroyasu Kaneda, Ken Takezawa, Kiyoko Kuwata, Haruka Yamaguchi, Erina Hatashita, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6219–6226.
https://doi.org/10.1158/1078-0432.CCR-12-0392
Published: 14 November 2012
View article titled, Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
Open the PDF for Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer in another window
Includes: Supplementary data